Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Novo Nordisk › The hits just kept coming for beleaguered Ozempic and Wegovy maker Novo Nordisk (NYSE: NVO) on Thursday. The company, which has been slammed with investor sell-offs since cutting its ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

GLP-1 weight loss medications like Ozempic and Wegovy could increase testosterone levels and help prevent erectile ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...